New Funding to Accelerate Scopio Labs' Commercial Growth and Product Innovation in Full-Field Digital Cell Morphology

新资金用于加速Scopio实验室在全场数字细胞形态学方面的商业增长和产品创新

PARSIPPANY, N.J. and TEL AVIV, Israel, July 25, 2024 /PRNewswire/ -- Scopio Labs, developer of Full-Field Digital Cell Morphology imaging and analysis platforms, today announced the successful completion of its Series D funding round, raising $42 million. This round was led by Fortissimo Capital, with participation from existing investors.

新泽西州帕西帕尼（PARSIPPANY）和以色列特拉维夫（Telaviv），2024年7月25日/PRNewswire/--全场数字细胞形态成像和分析平台的开发人员Scopio Labs今天宣布成功完成其D系列融资，筹集了4200万美元。本轮由Fortissimo Capital牵头，现有投资者参与。

The newly secured capital will fuel commercial expansion and accelerate the innovation of new products that leverage Scopio's Full-Field technology. This Series D brings Scopio's total fundraising to $130M..

新获得的资金将推动商业扩张，并加速利用Scopio全领域技术的新产品创新。这一系列的D使Scopio的总筹资额达到1.3亿美元。。

Scopio's breakthrough platform uses computational photography to provide unprecedented digital imaging of thousands of cells. Lab practitioners, therefore, have a full-field view of all regions of clinical interest on the sample at the highest resolution, supplanting the need for manual microscopy. By harnessing the power of clinical AI-based decision support combined with Full-Field digital imaging, Scopio delivers unparalleled workflow efficiency in blood cell analysis designed to enhance remote consultation and collaboration, expedite decision-making, and bolster patient care.

Scopio的突破性平台使用计算摄影技术为数千个细胞提供前所未有的数字成像。因此，实验室从业者可以以最高分辨率查看样品上所有临床感兴趣区域的全场视图，从而无需手动显微镜检查。通过利用基于临床AI的决策支持与全场数字成像相结合的强大功能，Scopio在血细胞分析中提供了无与伦比的工作流程效率，旨在增强远程咨询和协作，加快决策，并支持患者护理。

This platform not only amplifies diagnostic capabilities but also significantly curtails the time and expenses traditionally associated with manual methods..

该平台不仅扩大了诊断能力，而且大大缩短了传统上与手动方法相关的时间和费用。。

The Series D funding will enable Scopio to accelerate its market penetration and expand its global footprint. This includes scaling sales and marketing efforts and strengthening customer support. The funding will support the continued development of Scopio Labs' digital morphology platform and the creation of next-generation products to meet the evolving needs of hematology laboratories and hospitals..

D系列资金将使Scopio能够加速其市场渗透并扩大其全球足迹。这包括扩大销售和营销工作以及加强客户支持。这笔资金将支持Scopio实验室数字形态学平台的持续开发和下一代产品的开发，以满足血液实验室和医院不断变化的需求。。

'We are excited to have Fortissimo Capital lead our Series D funding round,' said Itai Hayut, Co-founder and CEO of Scopio Labs. 'This investment is a testament to the remarkable progress we have made and the immense potential of our technology. With the support of Fortissimo Capital and our existing investors, we are well-positioned to revolutionize the field of hematology and deliver unparalleled value to our customers.'.

Scopio实验室联合创始人兼首席执行官伊泰·海尤特（Itai Hayut）说，我们很高兴有Fortissimo Capital领导我们的D轮融资这项投资证明了我们取得的显著进步和我们技术的巨大潜力。在Fortissimo Capital和现有投资者的支持下，我们有能力彻底改变血液学领域，为客户提供无与伦比的价值。”。

'Scopio is experiencing a defining inflection point. The company's hematology solutions are transforming the manner in which labs analyze blood samples. We believe Scopio Labs will become the new global standard in digital cell morphology', said Yuval Cohen, Managing Partner at Fortissimo Capital. 'We look forward to supporting Scopio as it grows and enhances its leading position in the market.'.

“斯科皮奥正在经历一个决定性的转折点。该公司的血液学解决方案正在改变实验室分析血液样本的方式。Fortissimo Capital管理合伙人尤瓦尔·科恩（YuvalCohen）表示：“我们相信，Scopio实验室将成为数字细胞形态学的新全球标准。”。

About Scopio Labs

关于Scopio Labs

Scopio Labs is the developer of Full-Field imaging fueling the digital transformation of hematology laboratories worldwide. By supporting laboratory scientists and clinicians with unprecedented scale and depth in digital cell morphology, the company's platforms enable timely detection of blood-related medical conditions, expediting patients' access to life-saving treatments..

Scopio实验室是全场成像的开发人员，为全球血液学实验室的数字化转型提供了动力。通过在数字细胞形态学方面以前所未有的规模和深度支持实验室科学家和临床医生，该公司的平台能够及时检测血液相关的医疗状况，加快患者获得挽救生命的治疗。。

Scopio solves cell morphology's age-old trade-off between resolution and field of view. Its high-resolution imaging and embedded AI combine for more efficient remote workflow, contributing to better diagnostics across the continuum of care.

Scopio解决了细胞形态学在分辨率和视野之间的古老权衡。它的高分辨率成像和嵌入式AI结合在一起，实现了更高效的远程工作流程，有助于在整个护理过程中进行更好的诊断。

To learn more, visit www.scopiolabs.com.

To learn more, visit www.scopiolabs.com.

About Fortissimo

关于Fortissimo

Fortissimo Capital (www.ffcapital.com) is a leading private equity fund in Israel investing primarily in technology and industrial companies. Fortissimo's investment strategy is to achieve capital appreciation through taking a leading role and active approach in Israeli-related global businesses that require immediate and significant change, or stimulation of growth and by building business fundamentals to facilitate sustainable long-term growth and value creation..

Fortissimo Capital（www.ffcapital.com）是以色列领先的私人股本基金，主要投资于科技和工业公司。Fortissimo的投资战略是通过在以色列相关的全球业务中发挥领导作用和积极的方法来实现资本增值，这些业务需要立即进行重大变革或刺激增长，并通过建立业务基础来促进可持续的长期增长和价值创造。。

Some of Fortissimo's notable exits include: Kornit Digital IPO; SodaStream IPO; the sale of Diptech to Ferro, the sale of Nur Macroprinters to Hewlett Packard, the sale of Cadent to Align Inc., the sale of Breezometer to Google, the sale of Starhome to Telerix, the sale of Cardo to EMK, the sale of Biological Industries to Sartorius AG, and the sale of AOD Software Inc.

Fortissimo的一些值得注意的退出包括：Kornit Digital IPO；SodaStream IPO；将Diptech出售给Ferro，将Nur Macroprinters出售给Hewlett-Packard，将Cadent出售给Align Inc.，将Breezometer出售给Google，将Starhome出售给Telerix，将Cardo出售给EMK，将Biological Industries出售给Sartorius AG，以及出售AOD Software Inc。

to Primus Capital..

致Primus Capital。。

SOURCE Scopio Labs

SOURCE范围实验室